Oncobesity News Posts
Study finds bariatric surgery declined with rise in GLP-1 drugs to treat obesity
A new study has examined a large sample of privately insured patients with obesity and found that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as anti-obesity medications more than doubled from 2022 to 2023.
Are GLP-1 Drugs Putting an End to Bariatric Surgery?
(MedPage Today) —
In this video, Mikhail Varshavski, DO, who goes by “Dr. Mike” on YouTube, talks with Christine J. Ren-Fielding, MD, of NYU Langone Health in New York City, about the future of bariatric surgery.
Following is a partial transcript…
ADA Advises Against Compounded GLP-1s; Growth Hormone Therapy Guide; T1D Outcomes Up
(MedPage Today) — The American Diabetes Association (ADA) urged healthcare providers against prescribing non-FDA approved compounded GLP-1 and dual GIP/GIP-1 receptor agonists for type 2 diabetes or obesity and instead recommended switching to…
STAT+: Pharmalittle: We’re reading about menopause treatments, Novo plans for Wegovy in India, and more
Researchers presented new evidence that hormone therapy can be beneficial to menopausal women’s heart health
Why do Ozempic and Wegovy seem to treat everything?
From Alzheimer’s disease to depression to heart disease, Ozempic and other GLP-1 agonist drugs appear to offer a solution. Can one type of drug really tackle so many conditions, and if so, how does it actually work?
Is Bariatric Surgery at Risk of Becoming Obsolete?
With the advent of GLP-1 analogs, does bariatric surgery have a future role in helping people lose weight? Medscape Medical News
ADA Advises Against Using Compounded GLP-1 RA Medications
In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of safety issues. Medscape Medical News
Curbing plastics pollution could help reduce global burden of breast cancer, analysis suggests
A new study suggests addressing plastic pollution could play a critical role not only in protecting the environment, but also in lowering breast cancer rates, which have been increasing globally, especially in younger adults.
Olema in deal with Novartis on Kisqali breast cancer combo collaboration
Post Content This post firse appeared on Healthcare Articles on Seeking Alpha. Want to know more? Read More
Ozempic and other weight loss drugs could be making people drink less, study says
Another study suggests that weight-loss meds like Wegovy (NVO) and Mounjaro (LLY) can help people cut back on drinking alcohol.Read more…
Is 1-Week Radiotherapy Safe for Breast Cancer?
A new study found that 1-week ultrahypofractionated radiotherapy regimen for breast cancer was associated with acceptable late toxicities at 1 year. Medscape Medical News
Belly Fat Beats BMI in Predicting Colorectal Cancer Risk
Central obesity demonstrated a stronger association with colorectal cancer risk than general obesity measured using body mass index, according to a large UK cohort study. Medscape Medical News
ASH 2024: New Leukemia Txs, Fewer Blood Clots With GLP-1 Rxs
On tap at ASH this year: Presentations on improved therapies for ALL and CLL and reduced blood clots with weight loss drugs. Medscape Medical News
Tirzepatide Officially Puts GLP-1 Meds on the Map for Obesity-Related Heart Failure
(MedPage Today) — CHICAGO — A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying heart failure with preserved ejection fraction (HFpEF), according to the SUMMIT trial.
Incident…
Why some people don’t lose weight with Wegovy
Clinical trials have shown that people using weight-loss jabs, such as Wegovy and Mounjaro, lose anywhere between 16% and 21% of their body weight. But the drugs don’t work for everyone.
Does Screening at 40-49 Years Boost Breast Cancer Survival?
A recent analysis suggested improved survival for women screened for breast cancer at ages 40-49, whereas draft guidelines state the harms could outweigh the benefits. Medscape Medical News
Preventing holiday illness and navigating an ‘Ozempic Thanksgiving’
The Fox News Health Newsletter brings you trending and important stories about health care, drug developments, mental health issues, real people’s triumphs over medical struggles, and more.
Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy
This secondary analysis evaluates the ability of a 70-gene expression risk-of-recurrence assay, to identify the patients with early-stage breast cancer who could benefit the most from prolonged endocrine treatment.
Considerable cost savings from more efficient use of CDK4/6 inhibitors in metastatic breast cancer reported
On November 27, Nature published the results of an innovative breast cancer research project from the Netherlands. This study, the SONIA trial, showed that delaying and shortening the duration of a specific anti-cancer therapy (CDK4/6 inhibitors) in patients with hormone receptor-positive advanced breast cancer leads to similar survival outcomes, while reducing toxicity and achieving substantial cost reductions: over 45 million euros per year in the Netherlands and over 5 billion dollars in the United States.
IG Live December 2: The Weight of Wegovy
(MedPage Today) — MedPage Today spoke with experts during an Instagram Live 2 years ago about the growing buzz around GLP-1 receptor agonists and their role in transforming diabetes and obesity care. Since then, the use of medications like semaglutide…
Research shows death rates linked to obesity-related heart disease are up, especially among men
The rate of deaths from ischemic heart disease related to obesity nearly tripled in the U.S. over a two-decade span, according to new research. The rate for men more than tripled.
Tirzepatide shows powerful diabetes-prevention effect in three-year trial
Tirzepatide, a new injectable weight-loss drug, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to the results of a new study.
Semaglutide Rocketing Past Statins as Millions Eligible
A new study suggests that 40% of American adults have conditions that could benefit from semaglutide treatment. Medscape Medical News
Thanksgiving on Ozempic: Here’s how to enjoy the meal with a smaller appetite
For people taking Ozempic, Wegovy or other GLP-1 medications, Thanksgiving may look a little different. Experts give tips on how to handle challenges and enjoy the holiday.
How to preserve muscle mass on weight-loss drugs like Wegovy
Post Content This post first appeared on Mnt News RSS Feed Want to know more about it? Read More
GLP-1 Labels Don’t Reflect Trial Exclusions
Clinicians are advised to screen patients for conditions that would have rendered them ineligible to participate in the clinical trials. Medscape Medical News
Cheap Ozempic? How millions of Americans with obesity may get access to costly weight-loss drugs
Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 billion proposal from the Biden administration is blessed by President-elect Donald Trump
Thyroid Drug & Bone Loss; GLP-1s’ Renal Benefit; Menopause Musculoskeletal Syndrome
(MedPage Today) — The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the Radiological Society of North America’s annual meeting.
In a phase II study, investigational maridebart…
Alcohol Use and Antiobesity Medication Treatment
This cohort study examines the association of antiobesity medication use and alcohol use among participants enrolled in a weigh loss program.
Breast Cancer Incidence Still Rising Despite Decline in Death Rates
Despite the decline in death rates from breast cancer among women, the incidence of the disease has continued to rise in the US, by 1% a year from 2012 to 2021, according to an American Cancer Society analysis of data from the National Cancer Institute and the Centers for Disease Control and Prevention.
GLP-1 for Treating Obesity: 2024 Lasker-DeBakey Clinical Medical Research Award
In this Viewpoint, 2024 Lasker-DeBakey Clinical Medical Research Award winner Lotte Bjerre Knudsen describes her discovery of glucagon-like peptide-1 for the treatment of patients with obesity.
Biden will move to have Medicare, Medicaid cover GLP-1 weight-loss meds
The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid.
Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn’t impressed
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and potential Ozempic competitor MariTide, however, Wall Street wasn’t very impressed.Read more…
Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs
The Biden administration is looking to expand access to anti-obesity GLP-1 drugs like Ozempic and Wegovy for people who have Medicare and Medicaid.
Biden wants to expand access to Ozempic and other popular weight loss drugs
President Joe Biden is trying to expand access to pricey blockbuster drugs in his final months in office.Read more…
Younger Breast Cancer Patients Face Higher Recurrence Risk
A retrospective study found that younger patients with ER-positive, ERBB2-negative breast cancer are more prone to late distant recurrence. Medscape Medical News
GLP-1 RA Drugs Benefit People With SLE, Lupus Nephritis
The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss. Medscape Medical News
The Scan by 2 Minute Medicine®: Versatile Ozempic, Healthcare Reform, Unlocking the Brain, and Chickens and the Next Pandemic:
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. We begin with a discussion about Ozempic’s potential in treating alcohol use disorder. Then we take a closer look at how President-Elect Trump’s next term might affect healthcare.. After that, we examine a new therapy for
The post The Scan by 2 Minute Medicine®: Versatile Ozempic, Healthcare Reform, Unlocking the Brain, and Chickens and the Next Pandemic: first appeared on 2 Minute Medicine. Source: 2 Minute Medicine
Biden wants drugs like Wegovy, Ozempic covered by Medicare, Medicaid
Millions of Americans would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by Medicare and Medicaid under a rule the Biden administration has proposed.
Medicare moves to expand coverage for weight-loss drugs Wegovy, Zepbound
The Biden administration is proposing a major expansion of how Medicare and Medicaid cover the weight-loss drugs Wegovy and Zepbound.